JAG1

Across TCGA pan-cancer cohorts, JAG1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated JAG1 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher JAG1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated JAG1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

MESO, UCEC, and HNSC are the cancer types where JAG1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.098	0.579	.001	36	view →
UCEC	DFS	Median	All	0.977	0.596	<.001	36	view →
HNSC	OS	Median	All	0.239	0.609	.008	12	view →
BLCA	OS	Median	III,IV	0.879	0.340	.014	9	view →
LIHC	OS	Median	All	0.144	0.688	.031	9	view →
GBM	OS	Median	All	0.075	0.419	<.001	7	view →
LGG	OS	Median	All	0.270	0.799	.003	3	view →
STAD	OS	Median	III,IV	0.755	0.339	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

JAG1–MESO (OS)

Open the MESO breakdown →